heart failure – Page 2

Redefining Iron Deficiency in Heart Failure: Why TSAT and Serum Iron Outperform Ferritin for Prognosis

By MedXY 12/26/2025

Recent large-scale studies, including HEART-FID and major national registries, demonstrate that transferrin saturation (TSAT) and serum iron levels are more accurate predictors of functional capacity and mortality in heart failure than traditional ferritin-based definitions.

Cardiology Family Medicine & Nutrition news

Beyond Sodium Restriction: Legumes and Vegetables Linked to Improved Outcomes in Heart Failure

By MedXY 12/26/2025

A substudy of the global G-CHF registry demonstrates that higher intake of legumes and vegetables significantly reduces the risk of death and hospitalization in heart failure patients, while refined grains increase risk, highlighting the importance of food quality over simple nutrient restriction.

Cardiology Diabetes & Endocrinology news

Elevated Natriuretic Peptides: A Potent Predictor of Heart Failure and Mortality in Asymptomatic Diabetes

By MedXY 12/26/2025

A large-scale cohort study demonstrates that screening natriuretic peptide levels in individuals with type 1 or type 2 diabetes significantly predicts incident heart failure and death, advocating for routine biomarker-based risk stratification in this high-risk population.

Cardiology Diabetes & Endocrinology news

Intensive Lifestyle Intervention Reduces HFpEF Risk in High-Risk Diabetes: The Prescriptive Power of NT-proBNP

By MedXY 12/26/2025

A post-hoc analysis of the Look AHEAD trial demonstrates that NT-proBNP levels can identify patients with type 2 diabetes who benefit most from intensive lifestyle interventions. ILI significantly reduced HFpEF risk in those with elevated or stable/decreasing NT-proBNP, supporting a biomarker-guided approach to prevention.

Cardiology news

Finerenone and Hypotension Risk in Heart Failure: Evidence from the FINEARTS-HF Trial

By MedXY 12/26/2025

This analysis of the FINEARTS-HF trial identifies that while finerenone increases hypotension risk in HFmrEF and HFpEF patients, its clinical benefits persist. The study highlights key predictors of hypotension, such as low baseline blood pressure and advanced age, emphasizing the need for vigilant clinical monitoring.

Cardiology Infectious Diseases news

Sacubitril-Valsartan Shows Biological Activity in Chagasic Heart Failure: Insights from the ANSWER-HF Trial

By MedXY 12/25/2025

The ANSWER-HF trial compared sacubitril-valsartan to enalapril in patients with Chagasic heart failure. Although the primary endpoint of LVEF improvement was not met at 6 months, significant reductions in NT-proBNP and a favorable win ratio suggest biological activity and safety in this neglected population.

Cardiology news Oncology

High-Sensitivity Troponin I: A Poor Predictor of Anthracycline-Induced Left Ventricular Dysfunction?

By MedXY 12/25/2025

The Cardiac CARE trial reveals that high-sensitivity cardiac troponin I levels do not correlate with cumulative anthracycline dose and only weakly predict subsequent declines in left ventricular function, challenging existing risk-stratification models in cardio-oncology.

Cardiology news

Vutrisiran Redefines the Therapeutic Landscape for Transthyretin Amyloidosis with Cardiomyopathy: Comprehensive Insights from the HELIOS-B Trial

By MedXY 12/25/2025

The HELIOS-B trial demonstrates that vutrisiran significantly improves clinical outcomes, stabilizes cardiac biomarkers, preserves cardiac structure, and enhances the quality of life in patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM).

Cardiology news Radiology

Redefining Severity in Tricuspid Regurgitation: Why CMR-Derived Regurgitant Fraction and Liver Mapping Are the New Prognostic Gold Standards

By MedXY 12/25/2025

A landmark study in Circulation reveals that CMR-quantified tricuspid regurgitant fraction (TRF) ≥20% significantly increases mortality risk, while liver extracellular volume (L-ECV) mapping provides a novel, potent biomarker for systemic congestion and right heart failure outcomes.

Cardiology Internal Medicine news

Beyond Traditional Risk Scores: How Preclinical Measures Refine Heart Failure Prediction in the ARIC Study

By MedXY 12/24/2025

Recent findings from the ARIC study reveal that integrating cardiac biomarkers and echocardiography with the PREVENT-HF score significantly enhances the prediction of incident heart failure, identifying high-risk individuals who traditional clinical models might otherwise overlook.

Cardiology news

A Unified High-Sensitivity Cardiac Troponin I Threshold of 80 ng/L for Risk Stratification in Wild-Type Transthyretin Amyloid Cardiomyopathy

By MedXY 12/24/2025

This multicenter study identifies high-sensitivity cardiac troponin I (hs-cTnI) as a potent, independent predictor of mortality in wild-type transthyretin amyloid cardiomyopathy. A universal threshold of 80 ng/L, integrated with natriuretic peptides, provides a robust staging system across multiple assay platforms.

Cardiology Diabetes & Endocrinology news

Heart Failure Mortality: The Resilient Challenge in an Era of Declining Cardiovascular Deaths

By MedXY 12/20/2025

This multi-national analysis of 2.92 million deaths highlights a concerning trend: while coronary and stroke mortality have plummeted, heart failure mortality remains stagnant or rising, with people with diabetes bearing a disproportionate and unchanging excess risk over the last two decades.

AI Cardiology Clinical Updates news

Artificial Intelligence-Enabled Prediction of Heart Failure Risk From Single-Lead Electrocardiograms: A Multinational Cohort Review

By MedXY 12/05/2025

This review evaluates AI algorithms predicting heart failure risk from noisy single-lead ECGs, synthesizing evidence from large multinational cohorts, highlighting improved risk stratification with AI-ECG models beyond traditional clinical scores.

Cardiology news

Sudden Death Drives Excess Mortality in HFmrEF/HFpEF with EF <50% — Insights from FINEARTS‑HF

By MedXY 12/04/2025

In the FINEARTS‑HF trial, cardiovascular deaths comprised half of fatalities in HF with EF ≥40%, with sudden death accounting for the largest share — especially when EF was <50%. Finerenone did not clearly reduce cause‑specific mortality.

Cardiology Nephrology news

Comprehensive Summary of the FINEARTS-HF Trial Results on Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction

By MedXY 12/03/2025

The FINEARTS-HF trial demonstrates finerenone’s efficacy and safety in reducing heart failure events, improving symptoms, and lowering new-onset diabetes risk, with consistent benefits across sex, ejection fraction ranges, frailty levels, and recent heart failure worsening.

Cardiology news

Prioritizing SGLT2 Inhibitors Over MRAs as Third-Line Therapy in HFrEF? Nationwide Cohort Shows Lower Mortality with SGLT2 Initiation

By MedXY 12/02/2025

A Danish nationwide cohort study found that initiating SGLT2 inhibitors rather than mineralocorticoid receptor antagonists (MRAs) as the third foundational therapy after RASI and beta‑blocker in HFrEF was associated with lower all‑cause and cardiovascular mortality.

Cardiology Nephrology news

Declining Kidney Function Often Precedes Heart Failure Hospitalization in HFrEF — Track eGFR Slopes, Not Just Thresholds

By MedXY 11/29/2025

In HFrEF, eGFR often falls progressively for up to a year before heart-failure hospitalization or death. Monitoring eGFR trajectories provides earlier risk signals than single cut-offs and may identify patients for closer decongestion or therapy optimization.

Cardiology Clinical Updates Nephrology news

Comprehensive Review of the EMPEROR-Preserved Trial: Efficacy and Safety of Empagliflozin in Heart Failure with Preserved Ejection Fraction

By MedXY 11/28/2025

This review synthesizes the pivotal EMPEROR-Preserved Trial results, highlighting empagliflozin's efficacy in reducing heart failure outcomes in patients with preserved ejection fraction.

Cardiology news

Intracoronary Wharton’s Jelly Mesenchymal Stem Cells After STEMI Reduce Incident Heart Failure: Phase 3 PREVENT-TAHA8 Results

By MedXY 11/21/2025

A phase 3 randomized trial found intracoronary infusion of allogeneic Wharton’s jelly mesenchymal stem cells (WJ-MSCs) after STEMI reduced new-onset heart failure and HF readmissions and improved LVEF versus standard care over a median 33-month follow-up.

Cardiology Internal Medicine news

Mobile Integrated Health vs Transitions of Care in Heart Failure: Insights from the Mighty-Heart Trial

By MedXY 11/18/2025

A large clinical trial compared Mobile Integrated Health with standard care coordination for heart failure patients after hospital discharge, finding no significant overall benefits but highlighting potential age-related effects.